A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRIFOX
Our results indicate that patients with potentially resectable PDAC tend to have detectable KRAS in the blood if the disease is locally more advanced and that most patients who are treated with neoadjuvant NALIRIFOX are negative for KRAS at the end of therapy.
Authors
- Antonio Cubillo (ORCID: https://orcid.org/0000-0001-7511-7121)
- Paloma Peinado (ORCID: https://orcid.org/0000-0001-8851-5663)
- Carmen Toledano
- Teresa Macarulla (ORCID: https://orcid.org/0000-0002-1881-362X)
- Rafael Álvarez-Gallego (ORCID: https://orcid.org/0000-0002-3167-8039)
- Berta Laquente (ORCID: https://orcid.org/0000-0002-2477-1673)
- Enrique Sanz‐García (ORCID: https://orcid.org/0000-0002-3119-3832)
- Florian Castet (ORCID: https://orcid.org/0000-0002-5416-5383)
- Lisardo Ugidos
- Yolanda Quijano (ORCID: https://orcid.org/0009-0002-6626-591X)
- Juli Busquets (ORCID: https://orcid.org/0000-0001-6685-3135)
- César Muñoz (ORCID: https://orcid.org/0000-0002-1183-1307)
- Carles Fabregat-Franco (ORCID: https://orcid.org/0000-0003-2292-2690)
- Sharela Vega
- Emilio Vicente
Institutions
- Hebron University (PS)
- Bellvitge University Hospital (ES)
- Princess Margaret Cancer Centre (CA)
- Institut Català d'Oncologia (ES)
- HM Hospitales (ES)
- Hospital Universitario HM Sanchinarro (ES)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2025-09-10
- DOI
- https://doi.org/10.1097/coc.0000000000001253
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00